Autolus Therapeutics (AUTL) Assets Average (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Assets Average came in at $625.5 million in Q4 2025, down 22.31% YoY from $805.1 million in Q4 2024, and down 9.54% on a QoQ basis from $691.5 million in Q3 2025.
Autolus Therapeutics (AUTL) Assets Average (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Assets Average data on file, last reported at $625.5 million in Q4 2025.
- Quarterly Assets Average fell 22.31% year-over-year to $625.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $625.5 million (down 22.31% YoY) and the FY2025 annual result came in at $685.9 million, up 18.45% from the prior year.
- Assets Average fell to $625.5 million in Q4 2025, from $691.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $877.5 million in Q2 2024 to a low of $288.9 million in Q3 2022.
- A 5-year average of $522.2 million and a median of $442.0 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average soared 106.05% — and 2025, when it retreated 22.31%.
- Tracing AUTL's Assets Average over 5 years: stood at $351.1 million in 2021, then climbed by 7.39% to $377.1 million in 2022, then climbed by 3.63% to $390.7 million in 2023, then jumped by 106.05% to $805.1 million in 2024, then slipped by 22.31% to $625.5 million in 2025.
- The last three Assets Average figures came in at $625.5 million (Q4 2025), $691.5 million (Q3 2025), and $733.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 541.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 541.15 Mn |
| Dec 31, 2025 | 625.51 Mn |
| Sep 30, 2025 | 691.46 Mn |
| Jun 30, 2025 | 733.66 Mn |
| Mar 31, 2025 | 764.53 Mn |
| Dec 31, 2024 | 805.11 Mn |
| Sep 30, 2024 | 840.56 Mn |
| Jun 30, 2024 | 877.53 Mn |
| Mar 31, 2024 | 638.41 Mn |
| Dec 31, 2023 | 390.74 Mn |
| Sep 30, 2023 | 428.55 Mn |
| Jun 30, 2023 | 455.48 Mn |
| Mar 31, 2023 | 475.12 Mn |
| Dec 31, 2022 | 377.05 Mn |
| Sep 30, 2022 | 288.90 Mn |
| Jun 30, 2022 | 338.99 Mn |
| Mar 31, 2022 | 384.78 Mn |
| Dec 31, 2021 | 351.10 Mn |
| Sep 30, 2021 | 313.65 Mn |
| Jun 30, 2021 | 340.20 Mn |